Novartis Sees Sandoz U.S. Sales Extending Decline This Year
This article is for subscribers only.
Novartis AG said U.S. sales for Sandoz, its ailing generic-drugs unit, will continue to decline this year as the Swiss drugmaker weighs options including a potential sale.
Price pressure kept Sandoz’s operating profit stagnant last year, Novartis said Thursday. Meanwhile, earnings overall last quarter were less than analysts estimated at $1.40 a share.